Medtronic annual debt-to-ebitda ratio
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Medtronic Debt-to-EBITDA Ratio Growth & History (MDT)
Medtronic's debt-to-ebitda ratio was 2.90 for fiscal 2026.
View full Medtronic company overviewMedtronic annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-24 | 2.90 | −0.13 | −4.33% |
| 2025 | 2025-04-25 | 3.03 | −0.31 | −9.18% |
| 2024 | 2024-04-26 | 3.34 | 0.24 | +7.65% |
| 2023 | 2023-04-28 | 3.10 | 0.59 | +23.58% |
| 2022 | 2022-04-29 | 2.51 | −1.30 | −34.12% |
| 2021 | 2021-04-30 | 3.81 | 0.34 | +9.66% |
| 2020 | 2020-04-24 | 3.48 | 0.63 | +22.14% |
| 2019 | 2019-04-26 | 2.85 | 0.07 | +2.61% |
| 2018 | 2018-04-27 | 2.77 | −1.25 | −31.06% |
| 2017 | 2017-04-28 | 4.02 | 0.24 | +6.39% |
| 2016 | 2016-04-29 | 3.78 | −3.24 | −46.13% |
| 2015 | 2015-04-24 | 7.02 | 4.81 | +217.34% |
| 2014 | 2014-04-25 | 2.21 | — | — |
Medtronic quarterly debt-to-ebitda ratio
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-01-23 | 3.06 | 0.15 | +5.19% |
| Q2 2026 | 2025-10-24 | 3.00 | −0.06 | −1.90% |
| Q1 2026 | 2025-07-25 | 2.89 | −0.49 | −14.53% |
| Q4 2025 | 2025-04-25 | 3.03 | −0.31 | −9.18% |
| Q3 2025 | 2025-01-24 | 2.91 | 0.01 | +0.27% |
| Q2 2025 | 2024-10-25 | 3.06 | 0.19 | +6.44% |
| Q1 2025 | 2024-07-26 | 3.38 | 0.44 | +14.99% |
| Q4 2024 | 2024-04-26 | 3.34 | 0.24 | +7.65% |
| Q3 2024 | 2024-01-26 | 2.90 | 0.22 | +8.37% |
| Q2 2024 | 2023-10-27 | 2.87 | 0.45 | +18.44% |
| Q1 2024 | 2023-07-28 | 2.94 | 0.93 | +46.54% |
| Q4 2023 | 2023-04-28 | 3.10 | 0.59 | +23.58% |
| Q3 2023 | 2023-01-27 | 2.68 | −0.22 | −7.57% |
| Q2 2023 | 2022-10-28 | 2.42 | −0.77 | −24.13% |
| Q1 2023 | 2022-07-29 | 2.00 | −1.52 | −43.06% |
| Q4 2022 | 2022-04-29 | 2.51 | −1.30 | −34.12% |
| Q3 2022 | 2022-01-28 | 2.90 | −1.61 | −35.69% |
| Q2 2022 | 2021-10-29 | 3.20 | −0.97 | −23.28% |
| Q1 2022 | 2021-07-30 | 3.52 | 0.08 | +2.43% |
| Q4 2021 | 2021-04-30 | 3.81 | 0.34 | +9.66% |
| Q3 2021 | 2021-01-29 | 4.50 | 1.67 | +58.74% |
| Q2 2021 | 2020-10-30 | 4.17 | 1.30 | +45.44% |
| Q1 2021 | 2020-07-31 | 3.44 | 0.62 | +22.19% |
| Q4 2020 | 2020-04-24 | 3.48 | 0.63 | +22.14% |
| Q3 2020 | 2020-01-24 | 2.84 | 0.18 | +6.70% |
| Q2 2020 | 2019-10-25 | 2.86 | 0.17 | +6.37% |
| Q1 2020 | 2019-07-26 | 2.81 | 0.23 | +8.90% |
| Q4 2019 | 2019-04-26 | 2.85 | 0.07 | +2.61% |
| Q3 2019 | 2019-01-25 | 2.66 | −0.19 | −6.73% |
| Q2 2019 | 2018-10-26 | 2.69 | −0.23 | −7.93% |
| Q1 2019 | 2018-07-27 | 2.58 | −0.50 | −16.27% |
| Q4 2018 | 2018-04-27 | 2.77 | −1.25 | −31.06% |
| Q3 2018 | 2018-01-26 | 2.85 | −0.32 | −10.06% |
| Q2 2018 | 2017-10-27 | 2.92 | −0.54 | −15.57% |
| Q1 2018 | 2017-07-28 | 3.08 | −0.57 | −15.49% |
| Q4 2017 | 2017-04-28 | 4.02 | 0.24 | +6.39% |
| Q3 2017 | 2017-01-27 | 3.17 | −1.68 | −34.63% |
| Q2 2017 | 2016-10-28 | 3.46 | −1.83 | −34.61% |
| Q1 2017 | 2016-07-29 | 3.65 | −2.37 | −39.35% |
| Q4 2016 | 2016-04-29 | 3.78 | −3.24 | −46.13% |
| Q3 2016 | 2016-01-29 | 4.85 | — | — |
| Q2 2016 | 2015-10-30 | 5.30 | — | — |
| Q1 2016 | 2015-07-31 | 6.02 | — | — |
| Q4 2015 | 2015-04-24 | 7.02 | — | — |
Medtronic debt-to-ebitda ratio trends
Over the last five fiscal years, Medtronic's debt-to-ebitda ratio decreased from 3.81 to 2.90, a change of −0.91. The latest reported quarter, Q3 2026, shows 3.06.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medtronic source filings ↗Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...
